Cargando…

Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma

Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma. Twenty years ago, FL was considered an indolent lymphoma with a long survival time but without a high rate of complete remission with chemotherapies. The use of rituximab has improved the response and survival of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Feugier, Pierre, Filliatre-Clement, Lauriane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426075/
https://www.ncbi.nlm.nih.gov/pubmed/30906531
http://dx.doi.org/10.12688/f1000research.16686.1
_version_ 1783404947050594304
author Feugier, Pierre
Filliatre-Clement, Lauriane
author_facet Feugier, Pierre
Filliatre-Clement, Lauriane
author_sort Feugier, Pierre
collection PubMed
description Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma. Twenty years ago, FL was considered an indolent lymphoma with a long survival time but without a high rate of complete remission with chemotherapies. The use of rituximab has improved the response and survival of patients with this lymphoma. More recently, development of biological knowledge and use of targeted drugs have offered new perspectives, including improvement of response rates and survival with chemo-free treatment strategies. In 2019, patients have a 10-year overall survival probability of over 70%. Histological transformation to more aggressive lymphoma and treatment relapses remain a medical challenge, especially for patients relapsing within two years. This article will review the recent advances in the treatment of FL. As the use of new drugs is directly related to the development of biological aspects, we will first summarize recent advances in biological aspects of FL.
format Online
Article
Text
id pubmed-6426075
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-64260752019-03-21 Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma Feugier, Pierre Filliatre-Clement, Lauriane F1000Res Review Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma. Twenty years ago, FL was considered an indolent lymphoma with a long survival time but without a high rate of complete remission with chemotherapies. The use of rituximab has improved the response and survival of patients with this lymphoma. More recently, development of biological knowledge and use of targeted drugs have offered new perspectives, including improvement of response rates and survival with chemo-free treatment strategies. In 2019, patients have a 10-year overall survival probability of over 70%. Histological transformation to more aggressive lymphoma and treatment relapses remain a medical challenge, especially for patients relapsing within two years. This article will review the recent advances in the treatment of FL. As the use of new drugs is directly related to the development of biological aspects, we will first summarize recent advances in biological aspects of FL. F1000 Research Limited 2019-03-15 /pmc/articles/PMC6426075/ /pubmed/30906531 http://dx.doi.org/10.12688/f1000research.16686.1 Text en Copyright: © 2019 Feugier P and Filliatre-Clement L http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Feugier, Pierre
Filliatre-Clement, Lauriane
Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
title Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
title_full Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
title_fullStr Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
title_full_unstemmed Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
title_short Recent advances in the first-line treatment of follicular non-Hodgkin lymphoma
title_sort recent advances in the first-line treatment of follicular non-hodgkin lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426075/
https://www.ncbi.nlm.nih.gov/pubmed/30906531
http://dx.doi.org/10.12688/f1000research.16686.1
work_keys_str_mv AT feugierpierre recentadvancesinthefirstlinetreatmentoffollicularnonhodgkinlymphoma
AT filliatreclementlauriane recentadvancesinthefirstlinetreatmentoffollicularnonhodgkinlymphoma